The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Board approves five-year appointment, subject to shareholder nod through postal ballot
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Its a major breakthrough for women’s ovarian cancer care in Europe
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Subscribe To Our Newsletter & Stay Updated
